Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1283 Vaccine Boosters for SARS-CoV-2
NCT05137236Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Dec 2021
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mRNA-1283.251, mRNA-1283.211, mRNA-1283.529 in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Started Dec 2021; status: completed.
02
Drugs
mRNA-1283.251mRNA-1283.211mRNA-1283.529
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05137236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137236.